A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
NCT00240708 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 205
Last updated 2011-05-17
Summary
The purpose of this study is to evaluate the effectiveness and safety of risperidone, formulated as a long-acting injectable drug, compared with risperidone tablets in the treatment of patients with schizophrenia.
Conditions
Interventions
- DRUG
-
risperidone
Sponsors & Collaborators
-
Janssen Pharmaceutical K.K.
lead INDUSTRY
Principal Investigators
-
Janssen Pharmaceutical K.K. Clinical Trial · Janssen Pharmaceutical K.K.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-06-30
- Completion
- 2006-04-30
More Related Trials
-
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
NCT00558298 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
NCT01894984 ·Status: TERMINATED
-
A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication
NCT00256997 ·Status: TERMINATED ·Phase: PHASE4
-
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
NCT00495118 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
NCT00216580 ·Status: COMPLETED ·Phase: PHASE3
-
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
NCT00653406 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
NCT00246272 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
NCT01855074 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
NCT00563017 ·Status: UNKNOWN ·Phase: NA
-
A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
NCT00210717 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
NCT00297388 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
NCT00236548 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.
NCT00843687 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00236457 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00246259 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
NCT00269919 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
NCT00236353 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
NCT00589914 ·Status: COMPLETED ·Phase: PHASE3
-
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
NCT00774085 ·Status: COMPLETED
-
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
NCT00821600 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00246285 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
NCT00034775 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
NCT00246194 ·Status: COMPLETED